68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit. (June 2021)

• Record Type: Journal Article
• Authors: Lybik, Noah; Wale, Daniel J.; Wong, Ka Kit; Liao, Eric; Viglianti, Benjamin L.
• Is Part Of: Clinical nuclear medicine. Volume 46:Number 6(2021)
• Publication Date: 2021-06
• Subjects: DOTATATE -- pituitary adenoma -- somatostatin receptor imaging -- theranostics; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003589
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: In addition to gastroenteropancreatic neuroendocrine neoplasms, a wide variety of tumors express somatostatin receptors. Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. We describe the case of a 60-year-old man who underwent 68 Ga-DOTATATE PET/CT, demonstrating an avid invasive pituitary macroadenoma. This mass was persistent and refractory despite traditional treatment options. Because of the avidity, 177 Lu-DOTATATE therapy was offered, although not ultimately performed, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.